Zymogen activation peptides (ZAP) in the diagnosis of disease
US5356781A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Jun 26, 1991 |
| Grant date | Oct 18, 1994 |
| Priority date | — |
| Expiry date | Jun 26, 2011 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/845
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
Pancreatic disease can be diagnosed by assaying a patient's body fluid such as serum or urine, for pancreatic activation peptides (PAP) released from zymogens by proteolytic activation. Particularly useful are peptides having C-terminal D.sub.4 K sequences. The method uses polyclonal or monoclonal antibodies generated and selected for C-terminal specificity on PAP so that the tests only report free PAP not parent zymogen. Also described are peptides and antibodies labelled with revealing agents and/or immobilised on solid supports and their use in diagnostic assays and kits. In pancreatic disease the tests distinguish necrotising from oedematous acute pancreatitis and permit severity prediction and monitoring as well as diagnosing chronic pancreatitis in exacerbation. Tests reporting free activation peptides from the zymogens prophospholipase A, procolipase and proelastases are also applicable in non-pancreatic diseases where activation of these zymogens, sharing sequence homology in the activation peptide C-terminal region with pancreatic isoenzymes, forms part of the molecular pathology of the condition.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.